Previous reports using oral administration of anticancer probiotics analyzed the immunomodulatory effects of these live biotherapeutics on the colonic mucosae, highlighting the accumulation of IFNγ-producing CD8+ T cells as a surrogate marker of tumor immunosurveillance of cancers established in gut or extraintestinal locations. The gene discussed is IFNG; the disease is cancer.